Results 101 to 110 of about 950,345 (395)

Systemic treatment for hepatocellular carcinoma

open access: yesChronic Diseases and Translational Medicine, 2018
Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and
Manushi Aggarwal   +2 more
doaj   +1 more source

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma

open access: yesTuberculosis and Respiratory Diseases, 2016
Somatic mutations that lead to hyperactivation of epidermal growth factor receptor (EGFR) signaling are detected in approximately 50% of lung adenocarcinoma in people from the Far East population and tyrosine kinase inhibitors are now the standard first ...
Y. Chang, Chang-Min Choi, Jae Cheol Lee
semanticscholar   +1 more source

Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility. [PDF]

open access: yes, 2011
BackgroundCell migration plays an important role in many physiological and pathological processes, including immune cell chemotaxis and cancer metastasis.
Liao, Kan, Liu, Yang, Wang, Wenqi
core   +2 more sources

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

open access: yesMolecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice   +16 more
wiley   +1 more source

Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)

open access: yesКлиническая онкогематология, 2018
Background. Kinase domain mutations of BCR-ABL gene is the most common cause of tyrosine kinase inhibitor resistance. Aim. To present the data on prognostic value of BCR-ABL mutation burden in Russian patients over the last 10 years.
Vera Vyacheslavovna Tikhonova   +9 more
doaj   +1 more source

Tyrosine kinase inhibition produces specific alterations in axon guidance in the grasshopper embryo [PDF]

open access: yes, 1998
Tyrosine kinase signaling pathways are essential for process outgrowth and guidance during nervous system development. We have examined the roles of tyrosine kinase activity in programming growth cone guidance decisions in an intact nervous system in ...
Menon, Kaushiki P., Zinn, Kai
core  

Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways [PDF]

open access: yes, 2014
Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer’s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD þ ) from reduced nicotinamide adenine
Allison, Simon J.   +6 more
core   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model [PDF]

open access: hybrid, 2022
Hiroshi Ikeuchi   +6 more
openalex   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

open access: yesMolecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy